TRASTUZUMAB (Herceptin) prior authorization at Horizon Blue Cross Blue Shield of New Jersey
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Horizon Blue Cross Blue Shield of New Jersey reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Horizon Blue Cross Blue Shield of New Jersey's medical policy URL referenced in the cover letter
Horizon Blue Cross Blue Shield of New Jersey's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- OMNIA tier-1 vs tier-2 provider disputes
- Step therapy on biologics
- Behavioral health prior auth
- Out-of-state emergency reductions
TRASTUZUMAB (Herceptin)-specific denial patterns and context
Across payers (not just Horizon Blue Cross Blue Shield of New Jersey), TRASTUZUMAB (Herceptin)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Horizon Blue Cross Blue Shield of New Jersey denial sticks and the patient needs bridge access while appealing.
How Horizon Blue Cross Blue Shield of New Jersey approaches Biosimilars PAs
Horizon Blue Cross Blue Shield of New Jersey's Biosimilars reviewer typically anchors TRASTUZUMAB (ONTRUZANT) prior-auth decisions on step therapy on biologics. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at Horizon Blue Cross Blue Shield of New Jersey is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Horizon Blue Cross Blue Shield of New Jersey treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Horizon Blue Cross Blue Shield of New Jersey is domiciled in NJ, so unresolved appeals escalate to the NJ insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Only BCBS licensee in New Jersey; ~3.
If the PA is denied
Horizon Blue Cross Blue Shield of New Jersey gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.horizonblue.com/providers) with the same packet plus a peer-reviewed citation supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact Horizon Blue Cross Blue Shield of New Jersey
- Provider portal: https://www.horizonblue.com/providers
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for TRASTUZUMAB (Herceptin) prior auth?
Horizon Blue Cross Blue Shield of New Jersey's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Horizon Blue Cross Blue Shield of New Jersey?
Standard TRASTUZUMAB (Herceptin) PA decisions at Horizon Blue Cross Blue Shield of New Jersey: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Horizon Blue Cross Blue Shield of New Jersey most often reject TRASTUZUMAB (Herceptin) for?
Across Horizon Blue Cross Blue Shield of New Jersey's book the common rejection patterns include: OMNIA tier-1 vs tier-2 provider disputes; Step therapy on biologics; Behavioral health prior auth. For TRASTUZUMAB (Herceptin) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Can Horizon Blue Cross Blue Shield of New Jersey force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
Horizon Blue Cross Blue Shield of New Jersey can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Horizon Blue Cross Blue Shield of New Jersey fully-insured policies sits with the NJ insurance department.
How do I prep for a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Horizon Blue Cross Blue Shield of New Jersey
- Aflibercept at Horizon Blue Cross Blue Shield of New Jersey
- Apixaban at Horizon Blue Cross Blue Shield of New Jersey
- Atezolizumab at Horizon Blue Cross Blue Shield of New Jersey
- TRASTUZUMAB (Herceptin) at UnitedHealthcare
- TRASTUZUMAB (Herceptin) at Elevance Health
- TRASTUZUMAB (Herceptin) at Aetna
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com